The management of Parkinson's disease (PD) presents a clinical challenge due to its multifaceted nature. As a neurodegenerative disorder, PD is characterized by motor and non-motor symptoms that evolve over time, necessitating a comprehensive understanding of its pathophysiology, diagnosis, and treatment strategies.
PD primarily affects the dopaminergic neurons in the substantia nigra, leading to a dopamine deficit in the striatum. This results in the cardinal motor symptoms: bradykinesia, rigidity, and rest tremor. Additionally, PD involves non-dopaminergic pathways, contributing to non-motor symptoms such as autonomic dysfunction, cognitive impairment, and mood disorders.
PD diagnosis is primarily clinical, based on medical history and physical examination. However, the presence of non-motor symptoms and prodromal markers like REM sleep behavior disorder can aid early diagnosis. Neuroimaging techniques, including DaTscan and PET, can provide supportive evidence but are not diagnostic.
Management of PD is multidisciplinary, aiming to improve quality of life by controlling symptoms. Pharmacologic treatment is centered on dopamine replacement, with levodopa being the most effective. Dopamine agonists, MAO-B inhibitors, and deep brain stimulation are other therapeutic options. Non-motor symptoms require targeted treatment, often involving multiple specialties.
PD is a progressive disease with a variable course. Factors such as age at onset, rate of progression, and presence of non-motor symptoms can influence prognosis. Current research focuses on neuroprotective strategies and biomarkers for early diagnosis and personalized treatment.
Understanding the complexities of PD is crucial for its effective management. A comprehensive approach, considering both motor and non-motor symptoms, is key to improving the quality of life of patients. Ongoing research promises to enhance our understanding and provide more effective therapeutic strategies in the future.
1.
Discovery reveals protein involved in Parkinson's disease also drives skin cancer
2.
The prognosis of the Slovakian PM; Kate Middleton's treatment; and drug test cheating.
3.
We Don't Always Know What's 'Best' for Our Patients
4.
New tumor therapy approach reduces costs and side effects while increasing accessibility
5.
Dual-action mRNA vaccine takes aim at aggressive skin cancer
1.
The Evolving Arsenal: A 2025 Review of Antibody-Drug Conjugates and the Future of Precision Oncology
2.
Case Study: Combining Targeted Therapy with Immunotherapy for Metastatic Melanoma
3.
Anion Gap: The Simple Calculation That Reveals Much About Your Health
4.
Contemporary Methods in Hematology Across Clinical Settings
5.
Unlocking the Potential of Cytarabine: A New Era of Cancer Treatment
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
2.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VI
3.
An Eagles View - Evidence-based discussion on Iron Deficiency Anemia- Further Talks
4.
Iron Deficiency Anemia: Ferric Maltol As a New Treatment Option
5.
Current Scenario of Cancer- Palliative Care to Close the Care Gap
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation